{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-004974","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.274810+00:00","generated_at":"2026-05-23T03:40:29.182172+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Tonix Pharmaceuticals Presents Positive Preclinical Data on TNX-1700 for Gastric Cancer at AACR 2025","bullets":["At AACR 2025, Tonix showed TFF2-MSA (murine TNX-1700) plus anti-PD1 inhibited gastric tumor growth by 78.29% in mouse models.","Combination therapy activated cancer-killing CD8+ T cells and reduced immunosuppressive PMN-MDSCs in the tumor microenvironment.","TNX-1700 (hTFF2-HAS) is in preclinical development for gastric and colorectal cancers, with further studies planned.","Data demonstrated TFF2-MSA outperformed CXCR4 antagonist AMD3100 in reducing PMN-MDSC generation.","TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, supporting the therapeutic target."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-004974","json":"https://secwatch.observer/filing/0001999371-25-004974.json","markdown":"https://secwatch.observer/filing/0001999371-25-004974.md","text":"https://secwatch.observer/filing/0001999371-25-004974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125004974/0001999371-25-004974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125004974/tnxp-8k_042925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-23T03:40:29.182172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}